The Effect of Sputum Culture Results on The Duration of Hospitalization in Patients with Bronchiectasis

Yıl 2019, , 413 - 416, 25.12.2019

İclal Hocanlı , Mehmet Kabak , Barış Çil , Ahmet Doblan , İdris Kırhan

https://doi.org/10.35440/hutfd.625999

Öz

Background: The
aim of this study is to investigate whether sputum culture results (treatment
revision according to culture results) have an effect on the duration of
hospitalization in patients who were followed up with the diagnosis of
bronchiectasis in our clinic.

Materials and Methods: The
laboratory and radiological data of 23 patients who were followed up with the
diagnosis of bronchiectasis in the chest diseases clinic between January
2018-December 2018 were analyzed retrospectively. Demographic features, the
duration of hospitalization, the used antibiotics and antibiotic changes
according to the culture results were recorded for all patients.  The duration of hospitalization of patients
with and without culture growth was compared. In addition, the culture growing
group was evaluated in itself according to the growing microorganism type in
terms of the duration of hospitalization.

Results: While 39.1% (9
patients) of the patients had culture growth, 60.9% (14 patients) had no
culture (14 patients). Klebsiella pneumonia was detected in the culture of 4
patients, pseudomonas aeruginosa in the culture of 4 patients and mycobacterium
tuberculosis in the culture of 1 patient. Although the duration of
hospitalization was longer in patients with (10.1 ± 5.1 days) than those
without culture growth (7.8 ± 5.5 days), there was no significant difference
between two groups (p= 0.135). However, when patients with culture growth were
compared according to the microorganism type; it was detected that patients
with pseudomonas aeruginosa growth in the culture had significantly longer
duration of hospitalization.

Conclusion: Pseudomonas
aeruginosa is one of the most common grow microorganisms in sputum cultures of
patients with bronchiectasis. This factor increases the duration of
hospitalization of patients.

Bronşektazi Tanılı Hastaların Balgam Kültür Sonuçlarının Hastanede Kalış Süresine Etkisi

Öz

Amaç: Bu çalışmanın amacı, kliniğimizde
bronşektazi tanısıyla takip edilmiş hastaların balgam kültür sonuçlarının
hastanede kalış süresi üzerine etkisinin olup olmadığını araştırmaktır. 

Materyal ve metod: Ocak 2018-aralık 2018 tarihleri arasında göğüs hastalıkları kliniğinde bronşektazi tanısyla takip edilen,  23 hastanın laboratuvar ve radyolojik verileri retrospektif olarak incelendi.

Bulgular: Hastaların %39,1' de 
kültürde üreme olurken (9 hasta), %60,1'de kültürde üreme olmadı (14
hasta). 4 hastanın kültüründe klebsiella pnömoni, yine 4 hastanın
kültüründe  psödomonas aeruginosa ve 1
hastanın kültüründe de  myocobacterıum
tuberculosis üredi.kültür üremesi olan hastalar ile kültür üremesi olmayan
hastalar hastane yatış süreleri karşılaştırıldı.Kültürde üremesi saptanan
hastalarda (10.1±5.1 gün), kültürde üremesi saptanmayan hastalara (7.8±5.5 gün)
göre hastane yatış süresi daha uzun olmakla beraber istatiksel olarak anlamlı
bir farklılık tespit edilmedi (p=0.135). Ancak
kültürde  psödomonas aeruginosa üremesi olanların hastanede kalış süresi daha
uzun ve istatiksel olarak ta anlamlı idi.

Sonuç: Bronşektazi tanılı hastalarda kolonizasyon ve/veya enfeksiyon
sık görülmektedir. Balgam kültürlerinde en sık üreyen etkenlerden biri pseudomonas aeruginosadır ve bu etken
hastane yatış sürelerini arttırmaktadır. Çalışmamızda az sayıda olgu olmasına
rağmen, literatür verilerine  benzer
sonuçlar elde edilmiştir. Ancak daha etkili değerlendirmeler yapabilmek için
hasta sayısının daha yoğun olduğu benzer çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

bronşektazi, balgam kültürü, enfeksiyon

Kaynakça

• 1. Fishman AP. Bronchiectasis. In: Fishman AP, Elias JA, Fishman JA, et al (eds). Fishman’s Pulmonary Diseases and Disorders. 3rd ed. Vol 2. International Edition: Mc Graw-Hill, 1998: 2045-69.
• 2. Angrill J, Agusti C, Torres A. Bronchiectasis. Curr Opin Infect Dis 2001 ;14(2):193-7.
• 3. Barker A. Bronchiectasis. N Engl J Med 2002;346(18):1383-93.
• 4. N Kömüs, KC Tertemiz, A Akkoçlu, Z Gülay, E Yılmaz. Pseudomonas aeruginosa colonisation in bronchiectatic patients and clinical reflections. Tüberküloz ve Toraks Dergisi 2006; 54(4): 355-362.
• 5. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, Catalan Serra P, Ag¬ramunt Lerma M, Ballestin Vicente J, et al. Factors associated with bronc¬hiectasis in patients with COPD. Chest 2011;140(5):1130-1137. doi: 10.1378/chest.10-1758.
• 6. Martinez-Garcia MA, de la Rosa D, Soler-Cataluna JJ, Donat-Sanz Y, Cata¬lan Serra P, Agramunt Lerma M, et al. Prognostic Value of Bronchiectasis in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013 15;187(8):823-31. doi: 10.1164/rccm.201208-1518OC.
• 7. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(4):400-7.
• 8. Asthma And Bronchıectasıs Exacerbatıon Bei Mao, Jia-Wei Yang, Hai-Wen Lu, Jin-Fu Xu Eur Respir J. 2016;47(6):1680-6.
• 9. Asthma as aetiology of bronchiectasis in Finland. Mäntylä J, Mazur W, Törölä T, Bergman P, Saarinen T, Kauppi P. Respir Med. 2019;152:105-111. doi: 10.1016/j.rmed.2019.04.022.
• 10. Kartagener’s syndrome. Rodolfo Mendes Queiroz , Fred Bernardes Filho. Pan Afr Med J. 2018; 29: 160. doi: 10.11604/pamj.2018.29.160.14927.
• 11. Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15–9.
• 12. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101(8):1633-8.
• 13. Pang JA, Cheng A, Chan HS, et al. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and broncoalveolar lavage. Am Rev Respir Dis 1989 ;139(1):14-7.
• 14. Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60.
• 15. Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014 May;11(4):496-503. doi: 10.1513/AnnalsATS.201310-335OC.
• 16. Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in germany, 2005–2011: A population-based study of disease burden and trends. PLoS ONE 2013, 8, e71109. doi: 10.1371/journal.pone.0071109.
• 17. Seitz, AE, Olivier N, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the united states, 1993–2006. Chest 2010 Oct;138(4):944-9. doi: 10.1378/chest.10-0099.
• 18. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007;18 (2).
• 19. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, et al. The diseasemodifying effects of twice weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4(2):117-22.